Novel chemistry


Pradofloxacin, the active ingredient of Veraflox®, is a novel synthetic antimicrobial of the fluoroquinolone class and the 1st third-generation agent developed exclusively for veterinary medicine.

The molecule differs from other fluoroquinolones at three strategic positions, thus increasing favourable performance characteristics:

  1. The cyclopropyl group in position N1 controls overall antibacterial potency, contributes to Gram-negative activity and is regarded as the substituent of choice in this position.
  2. The presence of a pyrrolidino-piperidine substituent at the position 7 is associated with high Gram-negative activity and considerably greater Gram-positive activity, for both wild-type strains and those with reduced fluoroquinolone susceptibility. The addition also contributes to more favourable pharmacokinetics as higher lipophilicity and a longer half-life.
  3. The cyano group at position 8 has been shown to enhance the activity against first step fluoroquinolone-resistant strains of Staphylococcus aureus and Escherichia coli as shown by respectively reduced Mutant Prevention Concentration (MPC) values. Furthermore this substituent provides a moderate to absent phototoxic potential as well as the absence of retinal toxicity. In addition, activity against anaerobic bacteria involved in periodontal disease is markedly enhanced.
Rate this page

latest documents

3rd row with links